Improving Bladder Cancer Imaging Using 3-T Functional Dynamic Contrast-Enhanced Magnetic Resonance Imaging

ObjectivesThe objective of this study was to assess the capability of T2-weighted magnetic resonance imaging (T2W-MRI) and the additional diagnostic value of dynamic contrast-enhanced MRI (DCE-MRI) using multitransmit 3 T in the localization of bladder cancer. Materials and MethodsThis prospective study was approved by the local institutional review board. Thirty-six patients were included in the study and provided informed consent. Magnetic resonance imaging scans were performed with T2W-MRI and DCE-MRI on a 3-T multitransmit system. Two observers (with 12 and 25 years of experience) independently interpreted T2W-MRI before DCE-MRI data (maps of pharmacokinetic parameters) to localize bladder tumors. The pathological examination of cystectomy bladder specimens was used as a reference criteria standard. The McNemar test was performed to evaluate the differences in sensitivity, specificity, and accuracy. Scores of &kgr; were calculated to assess interobserver agreement. ResultsThe sensitivity, specificity, and accuracy of the localization with T2W-MRI alone were 81% (29/36), 63% (5/8), and 77% (34/44) for observer 1 and 72% (26/36), 63% (5/8), and 70% (31/44) for observer 2. With additional DCE-MRI available, these values were 92% (33/36), 75% (6/8), and 89% (39/44) for observer 1 and 92% (33/36), 63% (5/8), and 86% (38/44) for observer 2. Dynamic contrast-enhanced MRI significantly (P < 0.01) improved the sensitivity and accuracy for observer 2. For the 23 patients treated with chemotherapy, DCE-MRI also significantly (P < 0.02) improved the sensitivity and accuracy of bladder cancer localization with T2W-MRI alone for observer 2. Scores of &kgr; were 0.63 for T2W-MRI alone and 0.78 for additional DCE-MRI. Of 7 subcentimeter malignant tumors, 4 (57%) were identified on T2W images and 6 (86%) were identified on DCE maps. Of 11 malignant tumors within the bladder wall thickening, 6 (55%) were found on T2W images and 10 (91%) were found on DCE maps. ConclusionsCompared with conventional T2W-MRI alone, the addition of DCE-MRI improved interobserver agreement as well as the localization of small malignant tumors and those within bladder wall thickening.

[1]  P. Bendahl,et al.  Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol , 2013, Scandinavian journal of urology.

[2]  S. Sourbron,et al.  Interscanner Comparison of Dynamic Contrast-Enhanced MRI in Prostate Cancer: 1.5 Versus 3 T MRI , 2013, Investigative radiology.

[3]  M. Amin,et al.  The diagnostic accuracy of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the early detection and evaluation of bladder carcinoma: comparison with conventional cystoscopy , 2013, Abdominal Imaging.

[4]  S. Horenblas,et al.  Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study , 2012, Nuclear medicine communications.

[5]  A. Graser,et al.  Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. , 2012, Urology.

[6]  Maximilian Reiser,et al.  Quantification of Perfusion and Permeability in Multiple Sclerosis: Dynamic Contrast-Enhanced MRI in 3D at 3T , 2012, Investigative radiology.

[7]  Sadhna Verma,et al.  Urinary bladder cancer: role of MR imaging. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[8]  H. Sostman,et al.  Comparison of 1.5 and 3.0 T for Contrast-Enhanced Pulmonary Magnetic Resonance Angiography , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[9]  P. Lara,et al.  Progress in Personalizing Chemotherapy for Bladder Cancer , 2012, Advances in urology.

[10]  C. Nicolau,et al.  Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. , 2011, The British journal of radiology.

[11]  C. Kuhl,et al.  Dual-source parallel radiofrequency excitation body MR imaging compared with standard MR imaging at 3.0 T: initial clinical experience. , 2010, Radiology.

[12]  Carlos Nicolau,et al.  Diagnosis of bladder cancer: contrast-enhanced ultrasound , 2010, Abdominal Imaging.

[13]  Maximilian F. Reiser,et al.  Diffusion Tensor Imaging (DTI) of the Kidney at 3 Tesla–Feasibility, Protocol Evaluation and Comparison to 1.5 Tesla , 2010, Investigative radiology.

[14]  S. Lerner Innovations in endoscopic imaging for bladder cancer. , 2009, European urology.

[15]  Y. Tokuda,et al.  The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall , 2009, International Urology and Nephrology.

[16]  Tarek El-Diasty,et al.  Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging , 2009, European Radiology.

[17]  Alvin C. Goh,et al.  Application of new technology in bladder cancer diagnosis and treatment , 2009, World Journal of Urology.

[18]  K. Jhaveri,et al.  Magnetic resonance imaging of the urinary bladder: cancer staging and beyond. , 2008, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[19]  Xiangyu Yang,et al.  Improving the pharmacokinetic parameter measurement in dynamic contrast‐enhanced MRI by use of the arterial input function: Theory and clinical application , 2008, Magnetic resonance in medicine.

[20]  N. Holalkere,et al.  State-of-the-art cross-sectional imaging in bladder cancer. , 2007, Current problems in diagnostic radiology.

[21]  J O Barentsz,et al.  Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. , 2006, European urology.

[22]  S. Yun,et al.  Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging , 2006, European Radiology.

[23]  Dennis W J Klomp,et al.  Initial Experience of 3 Tesla Endorectal Coil Magnetic Resonance Imaging and 1H-Spectroscopic Imaging of the Prostate , 2004, Investigative radiology.

[24]  C. Matula,et al.  Magnetic Resonance Imaging Contrast Enhancement of Brain Tumors at 3 Tesla Versus 1.5 Tesla , 2002, Investigative radiology.

[25]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[26]  T. Mashimo,et al.  Evaluation of effect of treatment for invasive bladder cancer by ultrasonography with intra-arterial infusion of carbon dioxide microbubbles. , 1997, Investigative radiology.

[27]  W. J. Lorenz,et al.  Pharmacokinetic Mapping of the Breast: A New Method for Dynamic MR Mammography , 1995, Magnetic resonance in medicine.

[28]  D. Bluemke,et al.  UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Dynamic MRI of Bladder Cancer: Evaluation of Staging Accuracy , 2005 .

[29]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.